Full Press Release Details
Media
• October 23, 2023
IRWD Positive Sentiment
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
Key Takeaway: Ironwood Pharmaceuticals announced the release of new data regarding Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) at the American College of Gastroenterology 2023 Annual Scientific Meeting. This presentation highlights the company's ongoing research and commitment to improving treatment options for patients suffering from these conditions.
Price reaction · baseline $9.23 (2023-10-20 close) · 1 other IRWD headline(s) in the window, move may be shared
day 0 close · peak
-2.5%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood presented new data on IBS-C and CIC.
- The presentation occurred at a significant gastroenterology meeting.
- The findings may contribute to advancements in treatment options.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What data did Ironwood present at ACG 2023?
Ironwood presented new data on Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC).
Where was the Ironwood data presented?
The data was presented at the American College of Gastroenterology 2023 Annual Scientific Meeting.
What is the significance of the ACG meeting?
The ACG meeting is a significant event for advancements in gastroenterology research and treatment.